CBD

Researchers examined a half-dozen medical records involving CBD used to treat THC toxicosis in dogs.

This article examines what rescheduling cannabis would involve, the implications for various sectors, and the potential roadblocks that could arise along the way.

Here, Scott Mazza, Founder of Vitality CBD, discusses applying cannabidiol (CBD) in pets.

The five-year study will be supported by a $2.2 million grant from the National Institute of Drug Abuse.

The researchers point out that it is important for clinicians to ask about CBD use to better advise patients and prevent potential drug interactions.

The study found improvement in symptom relief with participants who used the suppositories, compared to the treatment-as-usual group.

A recent study targeting mild to moderate anxiety disorders showed that oral CBD can be a safe, effective treatment option.

This article provides an analysis of current regulations and proposed changes that could impact the hemp industry.

One study analyzed nearly 100 CBD products to test the accuracy of advertised cannabinoid content.

This month’s Healer webinar provided a deep dive into several studies on cannabis for various conditions.

In honor of National CBD Day on August 8 (8/8/24), we compiled eight articles on various aspects of cannabidiol (CBD).

California’s bill creating new restrictions on intoxicating hemp products has prompted responses citing negative impacts on patients and businesses.

This month’s webinar discussed studies conducted on cannabis and psychedelics for various conditions including anxiety and autism spectrum disorder.

This article will cover what the differences are between hemp and cannabis, the products that are on the market today, and why it is important to know where your product is coming from.

Here, Scott Mazza, Founder of Vitality CBD, compares the effects of the cannabis compounds CBD and THC for use with various conditions.

This month’s Healer webinar discussed several studies on cannabis and symptoms of dementia and cognitive decline.

At the Cannabis Science Conference Spring 2024, toxicologist Cristelle Santos provided a deep dive into the need for better cannabis product safety standards.

This article discusses the early experiments and studies on the effects of two cannabinoids on anxiety.

Given the fast and furious mobilization of the global healthcare community to understand the nature of the coronavirus, how to treat it, and, eventually, how to prevent it, the sheer volume of research on COVID-19 is not at all surprising. What is, perhaps, surprising, especially given how recently it’s been since the COVID-19 breakout, is that there are so many research publications on the potential for cannabis to be used to treat the virus. On the other hand, perhaps the abundance of research on cannabis for COVID-19 is not so surprising. After all, it is a virus that causes an immune response, which may escalate into a virulent inflammatory reaction. And an enormous body of research on cannabis—and cannabidiol (CBD) in particular—has shown cannabis to induce strong anti-viral and anti-inflammatory effects. It is still early days, so no clinical studies establishing the efficacy of cannabis for COVID-19 have yet been conducted, but studies have established several clear mechanisms of action for using cannabis to treat COVID-19.

This article reviews several studies on CBD dosages and what they mean for consumers and the industry.

As markets mature, manufacturing terpene blends have become a new art form and a differentiating factor for potential therapeutic applications. Here, we dive deeper into the insights of terpene formulation considerations.

In this blog installment, we take a deep dive into research on how cannabis affects neurodegenerative disorders such as Alzheimer’s disease, multiple sclerosis, and Parkinson’s disease.

A cannabis-based treatment was shown to be effective for cognitive disfunctions.

Our sister publication, Nutritional Outlook, recently published an article covering the year in CBD and looking ahead to what’s on the horizon in 2024.

A recent study examined adult use of four cannabinoids within the past year.